Soligenix, Inc. (NASDAQ:SNGX) shares are surging more than 70 percent after the company indicated that it would presents its results from its ricin toxin vaccine during the 20th annual conference on Vaccine Research. The conference is being held in Bethesda between April 24 and 26.
Soligenix indicated that Serum Antibody Profiling following vaccination disclosed a Correlate of Immunity to Ricin Toxin would be presented by its Chief Scientific Officer on April 25. The drug is its proprietary vaccine candidate for the prevention of exposure to ricin toxin, which uses a unique antigen that is fully devoid of the toxic activity of ricin.
The company revealed that it has assessing immune correlates of protection in animals sera vaccinated with RiVax. Its findings showed three key factors. The first is that the ThermoVax thermostabilization process considerably improves RiVax stability. The second is the degration in the antigen that could be assesses with particular monoclonal antibodies.
The third is that some monoclonal antibodies could be used to address the immune profile of vaccinated mice and primates. This would predict their survival following the ricin exposure challenge.
In a statement, Soligenix commented, “These findings are expected to facilitate the potential approval of the RiVax™ product under the U.S. Food and Drug Administration (FDA) “Animal Rule” and represent a significant step forward in the understanding of ricin toxin immunology.”
At time of writing this, the stock jumped 71.60 percent.